Compare Stocks: TFFP, ALVOW, APLMW, and ARAV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVOW Alvotech	$0.30 -6.3%	$0.21	$0.12 ▼ $3.00	N/A	N/A	4,596 shs	298 shs
APLMW Apollomics	$0.01	$0.02	$0.01 ▼ $0.23	N/A	N/A	57,956 shs	3,000 shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	$0.07	$0.06	$0.06 ▼ $3.23	N/A	N/A	N/A	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVOW Alvotech	0.00%	-21.03%	+99.87%	+1.18%	-73.91%
APLMW Apollomics	0.00%	-1.43%	-24.18%	-6.76%	0.00%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
TFFP TFF Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVOW Alvotech	$0.30 -6.3%	$0.21	$0.12 ▼ $3.00	N/A	N/A	4,596 shs	298 shs
APLMW Apollomics	$0.01	$0.02	$0.01 ▼ $0.23	N/A	N/A	57,956 shs	3,000 shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	$0.07	$0.06	$0.06 ▼ $3.23	N/A	N/A	N/A	N/A

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVOW Alvotech	0.00%	-21.03%	+99.87%	+1.18%	-73.91%
APLMW Apollomics	0.00%	-1.43%	-24.18%	-6.76%	0.00%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
TFFP TFF Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVOW Alvotech	N/A	N/A	N/A
APLMW Apollomics	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVOW Alvotech	$491.95M	N/A	N/A	N/A	N/A	N/A
APLMW Apollomics	$8.50M	N/A	N/A	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	$730K	0.40	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVOW Alvotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11/11/2026 (Estimated)
APLMW Apollomics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
ARAV Aravive	N/A	-$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	-$21.24M	-$6.44	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVOW Alvotech	N/A	N/A	N/A	N/A	N/A
APLMW Apollomics	N/A	N/A	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVOW Alvotech	N/A
APLMW Apollomics	N/A
ARAV Aravive	35.80%
TFFP TFF Pharmaceuticals	15.25%

Insider Ownership

Company	Insider Ownership
ALVOW Alvotech	N/A
APLMW Apollomics	N/A
ARAV Aravive	60.40%
TFFP TFF Pharmaceuticals	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVOW Alvotech	4	N/A	N/A	Not Optionable
APLMW Apollomics	59	N/A	N/A	Not Optionable
ARAV Aravive	20	N/A	N/A	No Data
TFFP TFF Pharmaceuticals	19	4.44 million	4.24 million	No Data

TFFP, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

June 30, 2026 | stockhouse.com

TFF Pharmaceuticals approves dissolution plan

March 8, 2025 | uk.investing.com

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

February 6, 2025 | prnewswire.com

TFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True Potential

December 12, 2024 | bovnews.comB

The TFFP Stock Mystery: Why Did TFFP Plunge Today?

December 6, 2024 | bovnews.comB

TFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?

November 23, 2024 | bovnews.comB

Stock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?

November 20, 2024 | bovnews.comB

TFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock Movements

November 19, 2024 | bovnews.comB

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%

November 15, 2024 | msn.com

TFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?

November 15, 2024 | bovnews.comB

TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down

November 14, 2024 | marketwatch.com

TFF Pharmaceuticals terminates employees, to wind down operations

November 14, 2024 | markets.businessinsider.com

TFF Pharmaceuticals to Dissolve and Liquidate Assets

November 14, 2024 | markets.businessinsider.com

TFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of Operations

November 14, 2024 | quiverquant.comQ

TFF Pharmaceuticals Announces It Will Wind Down Operations

November 14, 2024 | globenewswire.com

TFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News Summary

October 9, 2024 | benzinga.com

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

October 8, 2024 | zacks.com

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | finanznachrichten.de

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | markets.businessinsider.com

Post-COVID Trends in Biopharma Contract Manufacturing

September 25, 2024 | contractpharma.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

TFFP, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

$0.30 -0.02 (-6.25%)

As of 09/4/2026 10:03 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics NASDAQ:APLMW

$0.01 0.00 (0.00%)

As of 09/4/2026 03:33 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)

As of 09/4/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

TFF Pharmaceuticals NASDAQ:TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TFFP, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TFFP, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

Apollomics NASDAQ:APLMW

Aravive NASDAQ:ARAV

TFF Pharmaceuticals NASDAQ:TFFP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TFFP, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TFFP, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

Apollomics NASDAQ:APLMW

Aravive NASDAQ:ARAV

TFF Pharmaceuticals NASDAQ:TFFP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools